Herpes simplex virus 2 envelope glycoprotein (HSV-2 glycoprotein)

Herpes simplex virus 2 (HSV-2) envelope glycoproteins are a group of essential proteins located on the surface of the virus that facilitate its entry into host cells and its subsequent spread [4, 28]. The most critical members of this group include Glycoprotein D (gD), which mediates attachment to host receptors like nectin-1 and HVEM, and Glycoprotein B (gB), which acts as the primary fusion protein [2, 22, 33]. These glycoproteins work in a coordinated manner with the gH/gL complex to trigger the fusion of the viral envelope with the host cell membrane, a process necessary for the delivery of the viral genome into the host cell [4, 28]. In the context of disease, these proteins are the primary targets of the host's immune system, and their role in viral entry makes them prime candidates for therapeutic intervention [2, 6, 30]. While current treatments for HSV-2 infections primarily focus on inhibiting viral DNA replication, research into targeting envelope glycoproteins through vaccines and monoclonal antibodies aims to provide more effective prevention and treatment options [2, 3, 34]. Several investigational drugs, such as the monoclonal antibody UB-621 and various recombinant vaccines like Simplirix, have been designed to neutralize the virus by binding to these glycoproteins [16, 25, 35]. However, the high degree of immune evasion and the latent nature of HSV-2 infection present significant challenges to the development of successful glycoprotein-targeted therapies [2, 6, 32].

Other names

HSV-2 envelope glycoproteinsGlycoprotein D (gD)Glycoprotein B (gB)Glycoprotein C (gC)Glycoprotein G (gG)Glycoprotein H (gH)Glycoprotein L (gL)US6UL27UL44UL1UL22UL10UL53

Neutralization of viral entry by blocking the interaction between viral glycoproteins (e.g., gD) and host cell receptors (e.g., nectin-1, HVEM), or by inhibiting the membrane fusion process mediated by gB and the gH/gL complex. Vaccines targeting these glycoproteins aim to induce neutralizing antibodies and cellular immune responses to prevent infection or reduce viral reactivation and shedding.